Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results
Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results
复制标题
DOI：
10.1007/s003300000659
复制
发表时间：
2001-01-01
影响因子：
5.9
通讯作者：
Rocca, A
中科院分区：
文献类型：
--
作者：
Buscarini, L;Buscarini, E;Rocca, A
本研究的目的是通过长期随访评估经皮射频（RF）热消融治疗肝细胞癌（HCC）的有效性和安全性，并比较传统电极和可扩张电极。 88 名患有 101 个肝细胞癌结节（直径小于或等于 3.5 cm）的患者通过传统电极或可扩展电极接受了射频热消融。通过动态对比CT、血清甲胎蛋白水平、治疗结束时和随访期间的超声检查来评估治疗效果。平均 3.3 个疗程（常规电极治疗的肿瘤）或 1.5 个疗程（可扩张电极治疗的肿瘤）内所有肿瘤结节均获得完全坏死。平均随访时间为 34 个月； 5 年总生存率为 33%。 5 年无病生存率为 3%；使用传统电极治疗的患者局部复发率为29%；使用可扩张电极治疗的患者为 14%。观察到 2 例主要并发症和 14 例次要并发症。射频热消融治疗小肝癌非常有效，主要并发症的比例很低。使用可扩张电极大大减少了治疗次数，但没有改变总生存率和无病生存率。
The aim of this study was to evaluate the effectiveness and the safety of percutaneous radiofrequency (RF) thermal ablation of hepatocellular carcinoma (HCC) in 88 patients with a long follow-up, and to compare conventional electrodes and expandable electrodes. Eighty-eight patients with 101 hepatocellular carcinoma nodules (less than or equal to 3.5 cm in diameter) underwent RF thermal ablation by means of either conventional elect;odes or an expandable electrode. Therapeutic efficacy was evaluated with dynamic contrast CT, serum alpha -fete protein level, US examination at the end of the treatment, and during follow-up. Complete necrosis was obtained in all tumor nodules in a mean number of 3.3 sessions (tumor treated by conventional electrodes) or 1.5 sessions (tumor treated by expandable electrode). The mean follow-up was 34 months; overall survival rate was 33% at 5 years. Disease-free survival at 5 years was 3%; local recurrence rate was 29% in patients treated with conventional electrodes; 14% in patients treated with the expandable electrode. Two major complications and 14 minor complications were observed. Radiofrequency thermal ablation in small HCC is very effective with a low percentage of major complications. The use of an expandable electrode substantially reduced the number of treatment sessions but did not modify the overall survival rate and the disease-free survival rate.